Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2018 May 1;78(1):54–61. doi: 10.1097/QAI.0000000000001641

Figure 2.

Figure 2

(A) Time to hepatotoxicity during IPT and ART by pretreatment AST/ALT and HbsAg status. (B) Cross-tabulation showing the distribution of hepatotoxicity events by pretreatment AST/ALT and HBsAg status